CLDN6 and cancer: Stadler and colleagues constructed mRNA encoding bispecific antibodies that directly targeted CD3 and ovarian carcinoma-associated antigen claudin 6 (CLDN6) and eliminated OV-90 cancer cells upon consecutive injection of a polymer/lipid-based transfection reagent carrying CD3 × CLDN6 mRNA.